Medical/Pharmaceuticals
Lunit Announces Financial Results for the First Half of 2022
* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period * Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global pro...
2022-08-12 21:00
13662
WeTrade Group Inc. Announces US$50 Million Sales of Monkeypox Virus Test Kits to Parkway Medical Limited
BEIJING, Aug. 12, 2022 /PRNewswire/ -- WeTrade Group Inc. ("Wetrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company has entered into a s...
2022-08-12 18:34
8446
JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.
SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...
2022-08-12 10:13
2360
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology
PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...
2022-08-12 09:09
2957
Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID
SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ -- Panacell Biotech Co., Ltd.
said that NK cells, exosomes, and brown adipose-derived stem cells are
effective to treat patients with long COVID conditions, or post COVID-19
conditions, as well as those with terminal illness.
2022-08-10 22:00
3730
WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel
BEIJING, Aug. 10, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, officially singed the strategic partnership agre...
2022-08-10 20:36
3069
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient inAustralia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring...
2022-08-10 20:00
2447
UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections
HOUSTON, Aug. 10, 2022 /PRNewswire/ -- UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world's first total-body PET/CT scanner, 'uEXPLORER®,' recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecula...
2022-08-10 20:00
6449
Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board
An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expertise and a global network to help Asieris advance its innovative pipeline to serve patients worldwide. SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a glob...
2022-08-10 16:09
2310
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
Co-founder and Board Member Hong-hoi Ting, D.Phil. Appointed Chief Strategy Officer James McCarter, Ph.D. Named Vice President, Head of Radioisotope Technology Research William Diamond, Ph.D., Carl Ross, Ph.D. and Herbert Moore, Ph.D. Join Radioisotope Technology Advisory Board SHANGHAI and BR...
2022-08-10 12:00
2351
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...
2022-08-10 11:43
2694
iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform
* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized gene editing technology for unique modified-bacteriophages * To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ -- iNtRON ...
2022-08-10 09:00
2253
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjec...
2022-08-09 17:00
3183
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that it will report financial results for the first half year endedJune 30, 2022, on Wednesday, August 31, 2022. The Company will host an English virtual ...
2022-08-09 15:00
2522
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004
SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene
Biopharmaceutical ("Inmagene
2022-08-09 12:00
2349
BGI Ranks No. 1 among APAC and China Life Science Corporations for Seven Consecutive Years: 2022 Nature Index Annual Tables Revealed
SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- BGI has topped the Asia Pacific andChina life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables. With a 19 percent increase in its adjusted share metric, BGI ranked eighth among g...
2022-08-08 22:00
3107
PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the preclinical results of porustobart (HBM4003,or the HCAb 4003-2 in the research paper), a next-generation fully human heavy-chain antibody with a ...
2022-08-08 17:43
2672
The world's leading brand of fashionable colored masks officially launches on Amazon on August 8th from CSD, a professional disposable medical supplies manufacturer in Taiwan
TAIPEI, Aug. 8, 2022 /PRNewswire/ -- People dress according to mood, occasion,
and necessity - and the mask, which inherently occupies half of the face, is an
indispensable fashion accessory. On August 8th, COLO, a fashionable mask brand
with colorful designs, will debut onAmazon
2022-08-08 13:04
2373
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation
SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time,
ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252
targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from
U.S. Food and Drug Administration ("FDA").
2022-08-08 08:30
2147
Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy
SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured$20 million in Series Angel a...
2022-08-07 07:00
4085
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
2026-09-03 23:53
9890
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
7825
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
6973
